Riskpilot← Back to searchSign inGet full accessUNIPHARMA ApS
APSBankruptCVR 78881917Nygade 6Wholesale of pharmaceutical and medical goods · NACE 4646Est. 1985— employees
Revenue 2024
DKK 0
EBITDA margin
—
Equity ratio
-12403300.0%
Financial strength
Net profit 2024
DKK 0
| Revenue | DKK 0 | — |
| EBITDA | DKK 0 | — |
| Net profit | DKK 0 | — |
| Total assets | DKK 1 | — |
| Equity | DKK -124K | +0% |
| Employees | — | — |
Legal name
UNIPHARMA ApS
CVR number
78881917
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. august 1985
Share capital
DKK 125.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Company purpose
Selskabets formål er at drive handel og industri
Address
Nygade 6
Phone
+4533131811
Email
Reumert@hca37.dk
- Event
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -5 | -6 | -6 | -6 | -11 | -9 | -10 | -5 | -5 | — | 0 | 0 | 0 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -5 | -6 | -6 | -6 | -11 | -9 | -10 | -5 | -5 | 0 | 0 | 0 | 0 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -5 | -6 | -6 | -6 | -11 | -9 | -10 | -5 | -5 | 0 | 0 | 0 | 0 |
| Net financials | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5 | -0 | 0 | 0 |
| Profit before tax | -5 | -6 | -6 | -6 | -11 | -9 | -10 | -5 | -5 | -5 | -0 | 0 | 0 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -5 | -6 | -6 | -6 | -11 | -9 | -10 | -5 | -5 | -5 | -0 | 0 | 0 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 180 | 180 | 180 | 180 | 180 | 180 | 180 | 180 | 180 | 180 | 181 | 0 | 0 |
| Equity | 111 | 105 | 99 | 93 | 82 | 73 | 72 | 67 | 62 | 57 | 56 | -124 | -124 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 69 | 75 | 82 | 88 | 99 | 108 | 109 | 114 | 119 | 124 | 124 | 124 | 124 |
| Total debt | 69 | 75 | 82 | 88 | 99 | 108 | 109 | 114 | 119 | 124 | 124 | 124 | 124 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20122024
Equity ratio
-12403300.0%
This company
38.2%
Market median
-32469472% vs market
20122024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20122024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20122024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20122024
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PR Chief Executive Officer | Chief Executive Officer | 2014 | — | — |
Jd Management | Management | 1985 | — | — |
EM Audit | Audit | 1985 | — | — |
OR Management | Management | 2023 | — | — |
PB Unofficial title | Unofficial title | 2026 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 1997 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of UNIPHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Reumert | Chief Executive Officer | 0 companies |
| Jørgen de Muzquiz Reumert | Management | 0 companies |
| Erik Munk | Audit | 0 companies |
| Ole Reumert | Management | 0 companies |
| Pernille Bigaard | Unofficial title | 0 companies |